Hormone Therapy + Ribociclib for Breast Cancer

This trial explores whether hormone therapy with ribociclib is as effective as chemotherapy followed by the same hormone therapy in treating certain types of breast cancer. Ribociclib, a targeted cancer therapy, blocks enzymes that aid tumor cell growth, while hormone therapy reduces estrogen, which some tumor cells require for growth. Suitable candidates for this trial include postmenopausal women or men with high-stage breast cancer, a low risk of recurrence, and no prior chemotherapy or specific hormone therapies. As a Phase 3 trial, this research represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.

The trial protocol does not specify if you need to stop taking your current medications. However, you must not be using systemic hormone replacement therapy at the time of registration, and if you were, it needs to be stopped with an appropriate washout period (time without taking certain medications).

Research has shown that ribociclib, when combined with hormone therapy, is generally safe for treating breast cancer. Most side effects from ribociclib can be managed by adjusting the dose, allowing patients to continue treatment without major problems. One study found that 90.7% of patients taking ribociclib were free from invasive disease after three years.

Hormone therapy, using drugs like letrozole, anastrozole, or exemestane, is also well-tolerated. These treatments work by lowering estrogen levels, which can help slow or stop the growth of some breast cancers. Studies have shown no major safety differences between these drugs, so they are all considered safe options. However, some patients taking exemestane have reported stopping treatment early due to side effects.

Researchers are excited about these treatments for breast cancer because they combine hormone therapy with ribociclib, a CDK4/6 inhibitor that works by blocking specific proteins that help cancer cells grow. Unlike standard treatments that may only involve hormone therapy or chemotherapy, ribociclib adds a targeted approach, aiming to enhance the effectiveness of hormone therapy by interfering with cancer cell division. Additionally, this combination could potentially offer a more tailored treatment approach, targeting cancer cells more precisely and possibly reducing side effects compared to traditional chemotherapy. This unique mechanism gives hope for better outcomes and improved quality of life for patients.

Research has shown that ribociclib, when combined with hormone therapy, improves outcomes for breast cancer patients. In this trial, participants in Arm A will receive chemotherapy, hormone therapy (letrozole, anastrozole, or exemestane), and ribociclib. Participants in Arm B will receive hormone therapy and ribociclib without chemotherapy. One study found that combining ribociclib with letrozole increased the average survival time to nearly 64 months, compared to 51 months with letrozole alone. This finding suggests that ribociclib can extend the lives of breast cancer patients. Hormone therapies like letrozole, anastrozole, and exemestane are also effective, with about 90% of patients surviving for 8 years. These treatments work by lowering estrogen levels, which some breast cancer cells need to grow. Using ribociclib together with these hormone therapies shows promising results in managing breast cancer.¹²³⁶⁷